ALX Oncology (NASDAQ:ALXO) CEO Purchases $76,856.04 in Stock

Key Points

• ALX Oncology CEO Jason Lettmann acquired 71,163 shares of the company's stock at an average price of $1.08, increasing his total ownership to 305,121 shares.
• ALX Oncology's share price is currently at $1.09, following a 3.8% increase during midday trading.
• Wall Street analysts have issued mixed ratings on ALX Oncology, with five analysts rating it a Buy and one a Hold, amid a consensus price target of $3.30.

ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) CEO Jason Lettmann purchased 71,163 shares of the business's stock in a transaction dated Wednesday, September 17th. The stock was purchased at an average price of $1.08 per share, for a total transaction of $76,856.04. Following the completion of the acquisition, the chief executive officer owned 305,121 shares of the company's stock, valued at approximately $329,530.68. This represents a 30.42% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Jason Lettmann also recently made the following trade(s):

• On Tuesday, September 16th, Jason Lettmann bought 21,070 shares of ALX Oncology stock. The stock was purchased at an average cost of $1.07 per share, for a total transaction of $22,544.90.

ALX Oncology Stock Performance

NASDAQ:ALXO traded up $0.06 during trading hours on Monday, reaching $1.27. 738,990 shares of the stock were exchanged, compared to its average volume of 609,708. ALX Oncology Holdings Inc. has a twelve month low of $0.40 and a twelve month high of $2.08. The firm has a 50 day moving average of $0.83 and a 200 day moving average of $0.65. The company has a current ratio of 4.52, a quick ratio of 4.52 and a debt-to-equity ratio of 0.11.

ALX Oncology (NASDAQ:ALXO - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.49) EPS for the quarter, missing analysts' consensus estimates of ($0.46) by ($0.03). As a group, analysts anticipate that ALX Oncology Holdings Inc. will post -2.76 EPS for the current year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Invesco Ltd. acquired a new stake in ALX Oncology in the 1st quarter valued at about $46,000. AQR Capital Management LLC increased its position in ALX Oncology by 183.6% during the first quarter. AQR Capital Management LLC now owns 119,050 shares of the company's stock worth $74,000 after buying an additional 77,065 shares during the last quarter. Jane Street Group LLC bought a new stake in ALX Oncology in the second quarter valued at approximately $84,000. Nuveen LLC acquired a new stake in shares of ALX Oncology in the first quarter valued at approximately $103,000. Finally, Deutsche Bank AG boosted its stake in shares of ALX Oncology by 521.0% during the 4th quarter. Deutsche Bank AG now owns 101,113 shares of the company's stock worth $169,000 after acquiring an additional 84,830 shares during the period. 97.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen downgraded shares of ALX Oncology from a "hold" rating to a "sell" rating in a research note on Friday, June 6th. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $3.30.

ALX Oncology Company Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.